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Objective—Bexarotene (Targretin) is a clinically used antitumoral agent which exerts its action through binding to and
activation of the retinoid-X-receptor (RXR). The most frequent side-effect of bexarotene administration is an increase
in plasma triglycerides, an independent risk factor of cardiovascular disease. The molecular mechanism behind this
hypertriglyceridemia remains poorly understood.
Methods and Results—Using wild-type and LXR/-deficient mice, we show here that bexarotene induces hypertriglyc-
eridemia and activates hepatic LXR-target genes of lipogenesis in an LXR-dependent manner, hence exerting a
permissive effect on RXR/LXR heterodimers. Interestingly, RNA analysis and Chromatin Immunoprecipitation assays
performed in the liver reveal that the in vivo permissive effect of bexarotene on the RXR/LXR heterodimer is restricted
to lipogenic genes without modulation of genes controlling cholesterol homeostasis.
Conclusion—These findings demonstrate that the hypertriglyceridemic action of bexarotene occurs via the RXR/LXR
heterodimer and show that RXR heterodimers can act with a selective permissivity on target genes of specific metabolic
pathways in the liver. (Arterioscler Thromb Vasc Biol. 2009;29:1488-1495.)
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RXRs (retinoid-X-receptors) are ligand-activated tran-scription factors belonging to the nuclear receptor super-
family. Three subtypes (RXR, RXR, and RXR) have
been identified, which can be activated by natural (9-cis
retinoic acid, docosahexaenoic acid) or synthetic ligands,
called rexinoids.1 RXRs are regulators of a plethora of
pathophysiological processes with potential clinical implica-
tions. For instance, bexarotene (LGD1069, Targretin), a
rexinoid with potent and selective activity for RXR, , and
,2 is clinically used in the treatment of cutaneous T cell
lymphoma3 and has promising effects in other cancer forms
or dermatologic disorders like psoriasis.4 In addition, syn-
thetic RXR ligands exert beneficial glucose-lowering and
insulin-sensitizing effects as well as antiobesity actions in
animal models of insulin-resistance and diabetes,5 and bex-
arotene improves cholesterol homeostasis and inhibits the
development of atherosclerosis in a mouse model of mixed
dyslipidemia.6 However, similar to other rexinoids, bexaro-
tene administration induces an undesirable increase in plasma
triglycerides,7,8 an independent risk factor of cardiovascular
disease (CVD).9,10 Until now, the molecular mechanism
behind bexarotene-induced hypertriglyceridemia remains
unknown.
RXR is a unique nuclear receptor because it can modulate
gene transcription by forming either homodimers or het-
erodimers with several other nuclear receptors, such as the
peroxisome proliferator-activated receptors (PPARs), liver-
X-receptors (LXRs), farnesoid-X-receptor (FXRs), pregnane-
X-receptor (PXR), retinoic-acid-receptors (RARs), vitamin
D-receptor (VDR), and thyroid hormone receptor (TR).
These heterodimers have been further subclassified as per-
missive or nonpermissive heterodimers. This concept states
that permissive heterodimers formed by RXR and binding
partners are activatable by both RXR-specific and partner
specific ligands, whereas nonpermissive heterodimers can
only be activated by ligands specific for the binding partner.
Among the nuclear receptors which require RXR as an
obligate partner for their action and form permissive het-
erodimers are the PPARs, FXRs, and LXRs. As PPARs,11
FXRs,12 and LXRs13 are involved in the regulation of genes
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implicated in triglyceride metabolism, permissive ligand
activation of RXR by rexinoids could elicit responses of the
dimerization partner and as such modulate triglyceridemia.
However, whereas PPAR and FXR activation leads to
decreased plasma triglyceride levels, LXR activation in-
creases triglycerides,13 presenting the permissive RXR/LXR
heterodimer as a potential mediator of bexarotene-induced
hypertriglyceridemia.
LXRs (LXR and LXR) are nuclear receptors that are
activated by oxysterols or synthetic ligands such as
T0901317, and bind DNA as obligate heterodimers with RXR
at specific LXR response elements (LXREs) composed of a
direct repeat of 5-AGGTCA-3 spaced by 4 bases. LXR
activation regulates triglyceride metabolism and induces he-
patic steatosis and hypertriglyceridemia attributable, in part,
to increased hepatic fatty acid synthesis and VLDL secre-
tion13,14 by upregulation of both sterol regulatory element-
binding protein 1c (SREBP1c)13,15,16 and carbohydrate re-
sponse element-binding protein (ChREBP)17 expression.
Moreover, LXRs play an important role in the regulation of
cholesterol homeostasis,18,19 and their activation leads to the
induction of several genes implicated in reverse cholesterol
transport and mobilization of cholesterol, such as the ATP
binding cassette (ABC) transporters ABCA1, ABCG1,
ABCG5, ABCG8, and apolipoprotein E.20
Using wild-type mice and mice deficient for both
isoforms of LXR (LXR/-deficient mice), we show that
the permissive heterodimer RXR/LXR mediates
bexarotene-induced hypertriglyceridemia and hepatic lipo-
genesis in vivo. Surprisingly, RNA levels and chromatin
immunoprecipitation (ChIP) assays reveal that this LXR-
mediated effect of bexarotene in the liver is restricted to
genes implicated in triglyceride homeostasis and lipogen-
esis, without modulation of genes controlling cholesterol
homeostasis. These findings demonstrate that RXR het-
erodimers can act with a selective permissivity on target
genes of specific metabolic pathways.
Materials and Methods
Animal Experiments
All experiments were performed with the approval of the Pasteur
Institute review board, Lille France.
Bexarotene was synthesized in the Laboratoire de Chimie The´ra-
peutique (Faculte´ des Sciences Pharmaceutiques, Universite´ Lille
Nord de France, France).
Female C57BL6 (13 weeks of age) wild-type (n28) or LXR/
-deficient (n28) mice36,37 obtained from Jan-Åke Gustafsson’s
laboratory were divided into 4 groups (n7/group) and were treated
with the RXR agonist bexarotene (suspended in 1% carboxymeth-
ylcellulose at the doses of 30 or 100 mg/kg body weight [mpk]), the
LXR agonist T0901317 (30 mpk) or vehicle alone by oral gavage
once daily for 14 days. At the end of the treatment, blood was
collected by retro-orbital venipuncture under isoflurane anesthe-
sia after 4 hour of fasting (9 AM to 1 PM). Plasma was separated
by centrifugation (15 minutes, 4°C, 4000 rpm) and used within 3
days for biochemical analysis. Animals were weighed and eutha-
nized by cervical dislocation. Livers were removed immediately,
frozen in nitrogen, and stored at – 80°C for further analysis.
For expanded Material and Methods, please see supplemental
information (available online at http://atvb.ahajournals.org).
Results
Bexarotene Increases Plasma and
Hepatic Triglyceride Levels in an
LXR/-Dependent Manner
To determine whether LXRs are implicated in the
bexarotene-induced hypertriglyceridemia, wild-type mice and
mice lacking both LXR and LXR (LXR/-deficient
mice) were treated with the RXR agonist (bexarotene, 30 and
100 mpk), the LXR agonist (T0901317, 30 mpk), or vehicle
alone for 14 days (Figure 1A). In wild-type mice, the LXR
agonist induced a hypertriglyceridemia, an effect which was
not observed in LXR/-deficient mice. Interestingly, the
RXR agonist bexarotene also induced a robust dose-
dependent hypertriglyceridemia, which was strongly blunted
in LXR/-deficient mice. Thus, the RXR/LXR heterodimer
appears to be the principal mediator of the bexarotene-
induced hypertriglyceridemia.
Because LXR is a lipogenic transcription factor in the liver,
we analyzed whether bexarotene influences triglyceride me-
tabolism in the liver and whether these effects are mediated
by LXR (Figure 1B). As previously shown,13 the LXR
agonist T0901317 increased hepatic triglyceride levels in
wild-type but not in LXR/-deficient mice. Interestingly,
bexarotene induced a dose-dependent increase in hepatic
triglyceride concentration in wild-type but not in LXR/-
deficient mice. Thus, the bexarotene-induced hypertriglycer-
idemia and hepatic triglyceride accumulation are dependent
on the RXR/LXR pathway.
Bexarotene Induces Hepatic Lipogenic Genes in an
LXR/-Dependent Manner
To further explore the role of LXR in the effects of bexaro-
tene on hepatic triglyceride metabolism, the expression of
LXR-target genes implicated in lipogenesis (SREBP1c, FAS,
and SCD1) was measured by quantitative PCR (Figure 2). As
expected, LXR agonist administration robustly increased the
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Figure 1. RXR or LXR agonist treatment
increases plasma and hepatic triglyceride
levels in vivo in an LXR/-dependent
manner. Plasma (A) and hepatic (B) tri-
glyceride concentrations were measured
in LXR/-deficient mice () and wild-
type mice (f) gavaged with the RXR ago-
nist (bexarotene, 30 and 100 mpk), the
LXR agonist (T0901317, 30 mpk), or vehi-
cle alone for 14 days (n7 per group).
**P0.01, ***P0.001 vs wild-type mice
treated with vehicle; §P0.05, §§P0.01 vs
LXR/-deficient mice treated with vehicle.
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expression of SREBP1c, FAS, and SCD1 in wild-type mice,
an effect which was completely blunted in LXR/-deficient
mice. Interestingly, the mRNA levels of SREBP1c, FAS, and
SCD1 also displayed a strong dose-dependent increase on
bexarotene treatment in wild-type but not in LXR/-
deficient mice. To determine whether bexarotene could act
via other transcription factor pathways and nuclear receptor
heterodimers, RNA levels of ChREBP, a glucose-activated
lipogenic transcription factor, acylcoA oxidase (ACO,
PPAR target gene) and BSEP (FXR target gene; supple-
mental Figure IA) as well as Cyp3A11, CD36, and FAE
(PXR target genes; supplemental Figure IB) were measured.
Bexarotene treatment increased ChREBP, ACO, and BSEP
mRNA both in wild-type and in LXR-deficient mice (supple-
mental Figure IA), suggesting that ChREBP gene regulation
as well as the permissive heterodimers RXR/PPAR and
RXR/FXR do not participate in bexarotene-induced lipogen-
esis which occurs only in wild-type mice. Moreover, we
measured the expression of 5deiodinase type 1 (DIO1), a
RXR/TR target gene implicated in the metabolism of thyroid
hormones (supplemental Figure IA). Bexarotene treatment
decreased DIO1 expression in the liver to a similar extent in
wild-type and in LXR/-deficient mice, suggesting that
potential alterations in the thyroid axis do not contribute to
bexarotene-induced hypertriglyceridemia. Finally, Cyp3A11
was not modified in bexarotene-treated wild-type mice,
indicating that PXR does not appear to be implicated in
bexarotene-induced lipogenesis (supplemental Figure IB).
By contrast to Cyp3A11, CD36 and FAE (fatty acid
elongase) mRNA levels were strongly increased in
T091317-treated wild-type but not LXR-deficient mice,
suggesting that these genes are activated in a LXR- but not
PXR-dependent manner by T091317 (supplemental Figure
IB). CD36 expression was induced by bexarotene treat-
ment both in wild-type and LXR-deficient mice, suggest-
ing that CD36 is not implicated in bexarotene-induced
lipogenesis which is only observed in wild-type mice. FAE
expression was strongly increased in wild-type bexarotene-
treated mice, an effect which was strongly reduced in
LXR-deficient mice, suggesting that the lipogenic enzyme
FAE could be implicated in bexarotene-induced lipogene-
sis, similar as SREBP-1c, SCD1, and FAS.
These data show that bexarotene upregulates specific
hepatic LXR-target lipogenic genes via the permissive het-
erodimer RXR/LXR in vivo.
Bexarotene Increases RXR Binding to the LXREs
of Hepatic Lipogenic Genes
To investigate whether the activation of hepatic lipogenic
LXR-target genes was associated with an increased ability of
RXR complexes to bind LXREs in the promoters of these
genes, ChIP assays were performed on livers of mice treated
with the highest dose of the RXR agonist, the LXR agonist,
or vehicle alone (Figure 3). Antibodies directed against RXR
(Figure 3A) and RNA polymerase II (Figure 3B) were used,
and input as well as immunoprecipitated DNA was quantified
by real-time PCR using primers positioned around the
LXREs of these genes (Figure 3A) or within the gene (Figure
3B), respectively. The antibody against RNA polymerase II
recognizes both the nonphosphorylated and the phosphory-
lated extending forms of RNA polymerase II, and occupancy
within the gene can be used as a measure of transcriptional
activity.21 In wild-type mice, the RXR ChIP-PCR revealed
that both LXR and RXR agonist treatment increased the
recruitment of RXR on the LXREs of SREBP1c, SCD1, and
FAS genes (Figure 3A). RNA polymerase II ChIP-PCR
showed that this bexarotene and T0901317-induced RXR
recruitment was associated with increased RNA polymer-
ase II occupancy in the genes encoding SREBP1c, FAS,
and SCD1 in wild-type mice (Figure 3B). By contrast,
bexarotene-induced RXR recruitment to the FAS and
SREBP1c LXREs was abolished in the LXR/-deficient
mice, on bexarotene and T0901317 treatment, whereas a
small albeit significant increase was still observed on the
SCD1 LXRE (Figure 3A). These data suggest that RXR can
bind independent of LXR in the vicinity of this LXRE.
Moreover, in LXR/-deficient mice, neither bexarotene nor
T0901317 led to a significant increase of RNA polymerase II
occupancy on the SREBP1c and FAS genes. In keeping with
the modest LXR independent binding of RXR to the SCD1
gene, a modest bexarotene-induced recruitment of RNA
polymerase II was observed after bexarotene treatment.
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Figure 2. RXR or LXR agonist treatment induces hepatic lipo-
genic gene expression in mice in vivo in an LXR/-dependent
manner. Hepatic mRNA levels of SREBP1c, SCD1, and FAS
were measured in LXR/-deficient mice () and wild-type mice
(f) gavaged with the RXR agonist (bexarotene, 30 and 100
mpk), the LXR agonist (T0901317, 30 mpk), or vehicle alone for
14 days (n7 per group). Data normalized to 28S mRNA are
expressed as a percentage of the wild-type mice group treated
with vehicle alone, to which an arbitrary value of 100 was attrib-
uted. **P0.01 vs wild-type mice treated with vehicle, §P0.05,
§§P0.01 vs LXR/-deficient mice treated with vehicle.
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Altogether, both LXR and RXR agonist treatment increased
RXR binding to LXREs and increased RNA polymerase II
occupancy on hepatic lipogenic genes in wild-type mice but
not in LXR/-deficient mice.
Plasma Cholesterol Concentrations Are Increased
After LXR but not RXR Agonist Treatment
Because LXR is a major regulator of cholesterol homeostasis,
plasma cholesterol concentrations were also measured in
wild-type and LXR/-deficient mice treated with the LXR
and RXR agonists, respectively (Figure 4A). The LXR
agonist T0901317 increased plasma total cholesterol by
increasing both HDL-C and non–HDL-C in wild-type but
not in LXR/-deficient mice (Figure 4B and 4C). Hepatic
cholesterol content was not modified after T0901317
treatment (data not shown). Interestingly, plasma total
cholesterol, HDL-C, and non–HDL-C did not change on
treatment of wild-type and LXR/-deficient mice with
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Figure 4. LXR but not RXR agonist treatment increases
plasma cholesterol levels in vivo. TC (A), HDL-C (B), and non–
HDL-C (C) were measured in LXR/-deficient mice () and
wild-type mice (f) gavaged, as indicated, with the RXR ago-
nist (bexarotene, 30 and 100 mpk), the LXR agonist
(T0901317, 30 mpk), or vehicle alone for 14 days (n7 per
group). **P0.01, ***P0.001 vs wild-type mice treated with
vehicle.
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Figure 3. RXR or LXR agonist treatment
increases RXR recruitment to the LXREs
of lipogenic genes in vivo. ChIP assays
were performed using antibodies against
RXR (A) or RNA polymerase II (B) on liv-
ers of LXR/-deficient mice and wild-
type mice treated with vehicle alone,
bexarotene (100 mpk), or T0901317 (30
mpk). Recovery was determined by real-
time PCR using primers positioned at
the LXRE of SREBP1c, FAS, and SCD1
(A) or primers located in the body of the
gene (B). Beta-globin was used as a
control. *P0.05, **P0.01, ***P0.001
vs wild-type mice treated with vehicle,
§P0.05, §§P0.01, §§§P0.001 vs
LXR/-deficient mice treated with
vehicle.
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the RXR agonist bexarotene. Moreover, bexarotene treat-
ment did not influence hepatic cholesterol content (data
not shown). Thus, bexarotene-mediated RXR activation of
the RXR/LXR heterodimer does not influence plasma
cholesterol concentrations, whereas T0901317-induced
LXR activation of RXR/LXR increases plasma cholesterol
concentrations.
Hepatic LXR-Target Genes Implicated in
Cholesterol Homeostasis Are Induced by LXR but
not RXR Agonist Treatment
LXR influences cholesterol homeostasis in the liver by
regulating genes encoding proteins of the ATP binding
cassette transporter family.22,23 Therefore, the expressions of
these LXR-target genes were measured in the liver. In
wild-type mice, LXR agonist treatment induced a strong
increase in the expression of ABCG1, ABCA1, ABCG5, and
ABCG8, an effect which was totally absent in LXR/-
deficient mice (Figure 5). Notably, in contrast to lipogenic
LXR target genes, the hepatic mRNA levels of these LXR
target genes of cholesterol metabolism only displayed minor
or no responsiveness to RXR agonist treatment. Indeed,
bexarotene treatment only slightly influenced the mRNA
level of these genes and these effects were comparable
between wild-type and LXR/-deficient mice. These data
show that, in contrast to hepatic lipogenic genes, only
T0901317 induces hepatic LXR-target genes implicated in
cholesterol homeostasis via RXR/LXR in vivo, demonstrat-
ing that RXR/LXR heterodimers can act with a selective
permissivity on target genes of specific pathways in the liver.
To analyze whether bexarotene can modulate these LXR-
target genes of cholesterol homeostasis in another organ such
as the intestine, the expression of ABCG5 and ABCG8 as
well as NPC1L1 was measured in the jejunum. In contrast
to T091317, the bexarotene-induced decrease of NPC1L1
expression was not LXR-dependent. However, both bex-
arotene and T091317 increased intestinal ABCG5 and
ABCG8 mRNA levels in an LXR-dependent manner
(supplemental Figure II). These LXR-dependent increases
of ABCG5 and ABCG8 expression by bexarotene in the
intestine differ from the absence of LXR-dependent effects
of bexarotene on these genes in the liver, identifying
tissue-specific mechanisms of RXR/LXR heterodimer
permissivity.
RXR Recruitment on the LXREs of Hepatic Genes
Implicated in Cholesterol Homeostasis Is Induced
by LXR but not RXR Agonist Treatment
To determine how T0901317 and bexarotene affect RXR
recruitment to the LXREs of genes implicated in cholesterol
homeostasis, RXR ChIP-PCR was performed on livers of
mice treated with the highest dose of the RXR agonist, the
LXR agonist or vehicle alone (Figure 6A). LXR agonist
treatment increased RXR occupancy on a putative LXRE
sequence adjacent to the ABCG1 gene in wild-type mice but
not in LXR/-deficient mice. Even though ABCA1 has a
high basal LXRE occupancy by RXR, RXR recruitment on
the reported LXRE in the proximal promoter of ABCA1
also tended to increase in wild-type mice but not in
LXR/-deficient mice. Because the mouse LXREs in
ABCG5 and ABCG8 genes have not yet been character-
ized, we used computational analysis to identify the DR4
elements in the vicinity of these genes, and we identified 2
putative LXREs in the first intron of the ABCG8 gene.
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Figure 5. LXR but not RXR agonist treatment upregulates hepatic cholesterol genes in vivo. Hepatic mRNA levels of ABCG1, ABCA1,
ABCG5, and ABCG8 were measured in LXR/-deficient mice () and wild-type mice (f) gavaged, as indicated, with the RXR agonist
(bexarotene, 30 and 100 mpk), the LXR agonist (T0901317, 30 mpk), or vehicle alone for 14 days (n7 per group). Data normalized to
28S gene are expressed as a percentage of the wild-type mice group treated with vehicle alone, to which an arbitrary value of 100 was
attributed. *P0.05, **P0.01 vs wild-type mice treated with vehicle, §P0.05 vs LXR/-deficient mice treated with vehicle.
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Interestingly, LXR agonist treatment increased the recruit-
ment of RXR to these putative LXREs only in wild-type
mice, indicating that these sequences are indeed functional
LXREs. In keeping with ABCG1, ABCA1, ABCG5, and
ABCG8 being LXR target genes in the liver, RNA poly-
merase II ChIP-PCR demonstrated LXR agonist dependent
polymerase II occupancy in wild-type but not in LXR/-
deficient livers (Figure 6B). Interestingly, in contrast to the
LXR agonist, RXR agonist did not induce major changes
in RXR binding to the examined LXREs adjacent to genes
involved in cholesterol homeostasis neither in wild-type
nor in LXR/-deficient liver. Moreover, recruitment of
RNA polymerase II to the ABCG1, ABCA1, ABCG5, and
ABCG8 genes was not influenced by bexarotene in wild-
type and in LXR/-deficient mice (Figure 6B). These
data demonstrate that LXR and RXR agonists differently
regulate RXR binding on hepatic genes implicated in
cholesterol homeostasis, an effect that may contribute to
their distinct effects on plasma and hepatic lipid levels.
Discussion
In the present study, we show that bexarotene, a rexinoid used
clinically for the treatment of certain cancers and dermato-
logic disorders, induces hypertriglyceridemia in an LXR-
dependent manner in vivo. This observation is of particular
importance because rexinoids have been proposed for the
treatment of metabolic diseases and insulin-resistance syn-
dromes. However, side effects such as hypertriglyceride-
mia,24,25 which is now widely recognized to be an indepen-
dent risk factor of CVD,9 have limited their use. Until now,
the mechanism underlying this effect was not understood. In
a study performed in ZDF rats treated for 14 days with a
broad range of bexarotene doses, the authors proposed that
the bexarotene-induced dose-dependent hypertriglyceridemia
was attributable to elevated VLDL caused by a primary
defect in LPL activity mainly in the muscle.26 Another study
performed in wild-type and PPAR-deficient mice suggested
2 separate pathways to explain bexarotene action on plasma
triglyceride concentrations, a PPAR-dependent pathway by
activation of the RXR/PPAR heterodimer for a TG-
decreasing effect of bexarotene and a PPAR-independent
pathway for the TG-raising effect of bexarotene but without
identifying the heterodimer implicated.27 As a previous study
performed in our laboratory in the apolipoprotein E2
knock-in mouse model showed a bexarotene-induced hyper-
triglyceridemia associated with an increase in the hepatic
expression of FAS and SCD1, 2 direct LXR-target genes
implicated in lipogenesis,6 we assessed whether hypertriglyc-
eridemia induced by the RXR agonist bexarotene could
involve the RXR/LXR pathway. Indeed, the heterodimer
RXR/LXR is known to be permissive, and the activation of
this heterodimer by LXR agonists induces hepatic steatosis
and hypertriglyceridemia.13,14 By measuring plasma triglyc-
eride concentrations in wild-type and LXR/-deficient
mice, we demonstrated that bexarotene-induced hypertriglyc-
eridemia occurred in a dose-dependent manner through the
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Figure 6. LXR but not RXR
agonist treatment increases
RXR recruitment to the LXRE
of cholesterol genes in vivo.
ChIP assays were performed
using antibodies against RXR
(A) or RNA polymerase II (B) on
livers of LXR/-deficient mice
and wild-type mice treated
with vehicle alone, bexarotene
(100 mpk), or T0901317 (30
mpk). Recovery was deter-
mined by real-time PCR using
primers positioned at the LXRE
of ABCA1, ABCG1, and at 2
putative LXREs of ABCG5 and
ABCG8 (A) or primers located
in the body of the gene (B).
Beta-globin was used as a
control. *P0.05, **P0.01 vs
wild-type mice treated with
vehicle.
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RXR/LXR pathway. This effect was associated with an
upregulation of hepatic lipogenic genes (SREBP1c, FAS,
FAE, and SCD1) in a dose- and LXR-dependent manner. The
implication of other heterodimers as mediators of the effects
of bexarotene in the liver was also analyzed. Bexarotene
activation of the permissive heterodimers RXR/PPAR or
RXR/FXR was not affected by LXR deficiency because
both ACO (RXR/PPAR target gene) and BSEP (RXR/FXR
target gene) expression was strongly increased by bexaro-
tene in wild-type and LXR/-deficient mice. The poten-
tial role of the thyroid hormone axis in the triglyceride
response to bexarotene was also dismissed because of the
fact that bexarotene decreased DIO1 (RXR/TR target
gene) expression to a similar extent in wild-type and
LXR/-deficient mice. Cyp3A11 (RXR/PXR target gene)
expression was not modified in the liver of bexarotene-
treated wild-type mice, suggesting that RXR/PXR het-
erodimers do not mediate bexarotene-induced lipogenesis
in wild-type mice.
The fact that the RXR/LXR heterodimer mediates
bexarotene-induced hypertriglyceridemia suggests that it
could also be implicated in hypertriglyceridemia reported
in vivo with many other RXR agonists.26,28 It is, however,
difficult to extrapolate to other rexinoids because each
rexinoid selectively activates its own pattern of het-
erodimers.29,30 However, LG10506, a new rexinoid shown
to selectively activate RXR/PPAR but not RXR/LXR,
RXR/RAR, and RXR/FXR heterodimers, has beneficial
metabolic effects without inducing hypertriglyceridemia,31
reinforcing the hypothesis that, in case of RXR agonist-
induced hypertriglyceridemia, LXR seems to be the main
partner implicated.
Notably, the results of this study support a new interesting
concept concerning the molecular mechanisms of RXR
heterodimer action. Indeed, we identify the existence of
heterodimer-specific selective permissivity on target genes
of specific metabolic pathways in one given tissue, ie, the
liver. The concept of selective permissivity linked to
tissue-specific activity has previously been introduced
with respect to RXR heterodimers.32 The heterodimer
RXR/TR, which was shown to be nonpermissive, displays
a permissive activity depending on the cell type.33–35
Conversely, the heterodimer RXR/FXR, shown to be
permissive in different assays in vitro, can be antagonized
by RXR agonists.32 Taken together, these studies have
demonstrated tissue-specific differences in permissivity of
certain RXR heterodimers. This concept has been extended
in our study to the LXR/RXR heterodimer, because bex-
arotene treatment increased ABCG5 and ABCG8 mRNA
levels in an LXR-dependent manner in the jejunum, but not
in the liver, suggesting the existence of distinct molecular
mechanisms of LXR target gene regulation in the intestine
versus the liver. Moreover, we show that, in liver, RXR
heterodimers can also act with a selective permissivity on
specific metabolic pathways. Indeed, similar to the LXR
agonist T0901317, bexarotene increased the recruitment of
RXR on the LXREs of specific LXR-target genes impli-
cated in hepatic lipogenesis (SREBP1c, SCD1, and FAS),
leading to their upregulation and hepatic accumulation of
triglycerides. Thus, the RXR/LXR heterodimer is permis-
sive for lipogenesis in the liver. By contrast, whereas the
LXR agonist induces the recruitment of RXR on the
LXREs of hepatic genes encoding proteins implicated in
cholesterol homeostasis, leading to a strong increase of
their expression in an LXR-dependent manner, the RXR
agonist bexarotene only slightly increased the expression
of these genes and did not influence liver and plasma
cholesterol homeostasis, either in wild-type or in LXR/
-deficient mice. Taken together, these results demon-
strate that the heterodimer RXR/LXR is nonpermissive for
cholesterol homeostasis in the liver. Thus, these data show
that, in the same organ (ie, the liver in our study), an RXR
heterodimer (in this case RXR/LXR) may be permissive
for target genes of specific metabolic pathways. These
observations reinforce the concept that rexinoids can have
molecule-, intertissue-, and intratissue specific effects,
which may find application in drug development by
synthesizing RXR modulators with appropriate tissue and
gene selective profiles for a potential clinical use.
In conclusion, this study shows that the molecular mech-
anism of bexarotene-induced hypertriglyceridemia is depen-
dent on the RXR/LXR pathway and that in liver the in vivo
permissive effect of bexarotene on the RXR/LXR het-
erodimer is restricted to specific lipogenic LXR-target genes
but does not affect LXR-target genes implicated in choles-
terol homeostasis. In addition, our study supports the notion
of selective permissivity on target genes of specific metabolic
pathways for the mode of action of RXR heterodimers.
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 
Supplement Material 
 
Supplemental Materials and Methods 

Plasma parameters 
Plasma concentrations of total cholesterol (TC) and triglycerides (TG) were measured using 
commercially available kits (Biomerieux, France). HDL-cholesterol (HDL-C) concentrations were 
determined in plasma after precipitation of apolipoprotein (apo) B-containing lipoproteins using 
phosphotungstic acid/Mg (Boehringer Mannheim, Germany). Non-HDL-cholesterol (N-HDL-C) was 
calculated by subtraction of HDL-C values from TC.  
 
Hepatic lipid analysis 
Frozen liver tissue (50 mg) was homogenized in SET buffer (1 mL ; sucrose 250 mM, EDTA 2 mM and 
Tris 10 mM), followed by two freeze-thaw cycles and three times passing through a 27-gauge syringe 
needle and a final freeze-thaw cycle. Protein content was determined with the BCA method and TG 
and cholesterol measured as described above. 
 
RNA extraction and quantitative PCR analysis 
RNA, isolated from the liver using the acid guanidinium thiocyanate/phenol/chloroform method 
(Chomczynski et al.), was reverse transcribed using random hexamer primers and Moloney murine 
leukemia virus-reverse transcriptase (Invitrogen, France). RNA levels were determined by real-time 
quantitative PCR on the MX-4000 apparatus (Stratagene) using the Brilliant SYBR Green QPCR 
master mix (Stratagene) and specific primers listed in Supplemental Table 1 (Eurogentec). Results are 
expressed normalized to 28S RNA. 
Reference: 
Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-
phenol-chloroform extraction. Anal Biochem. 1987;162:156-159. 
 
Chromatin Immunoprecipitation (ChIP) Assay 
 
For each ChIP experiment, chromatin was prepared from approximately 30 mg of liver as described 
(Nielsen et al.). Chromatin IP was carried out as described using anti-RXR (sc553, Santa Cruz 
 
biotechnologies) and anti-RNA polymerase II antibodies (AC-0555-100, Diagenode). Precipitated DNA 
was analyzed by quantitative PCR. Primer sequences can be acquired upon request. DR4 elements in 
adjacent to the ABCG5 and 8 genes where carried out using the NHR scan algorithm 
(www.cisreg.ca/cgi-bin/NHR-scan/nhr_scan.cgi ; Sandelin and Wasserman) 
 
References: 
Nielsen R, Grontved L, Stunnenberg HG, Mandrup S. Peroxisome proliferator-activated receptor 
subtype- and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery. 
Mol Cell Biol. 2006;26:5698-5714. 
Sandelin A, Wasserman W. Prediction of nuclear hormone receptor response elements. Mol Endo. 
2005;19:595-606. 
  
Statistical analysis 
Values are presented as mean ± sem. Data comparison between more than two groups was 
determined by ANOVA, using the SPSS software. Significant differences were then subjected to post-
hoc analysis by using the Scheffe-test. A value of p<0.05 was accepted as statistically significant. 
 


 
Supplemental Table 1 : Primers used for real-time PCR 

Gene Forward primer Reverse primer 
28S 5’-AAACTCTGGTGGAGGTCCGT-3’ 5’-CTTACCAAAAGTGGCCCACTA-3’ 
SREBP1C 5’-GTTACTCGAGCCTGCCTTCAGG-3’  5’-CAAGCTTTGGACCTGGGTGTG-3’  
FAS 5’-GGTATGTCC GGGAAATTGCC-3’  5’-ATTGTGTGTGCCTGCTTGGG-3’  
SCD1 5’-TTCCGTCCTGCAAGCTCTACACCTG-3’  5’-AGCCGTGCCTTGTAAGTTCTGTGG-3’  
ABCA1 5'-ACACCTGACACACCAGCTACAAGGC-3' 5'-TGAGTTCTTCCCACATGCCTTCC-3' 
ABCG1 5’-CCTTCAGCATCATGCG-3’ 5’-CCGATCCCAATGTGCGA-3’ 
ABCG5 5'-TGGCCCTGCTCAGCATCTCTG-3' 5'-GGATTTTTAAAGGAATGGGCATCTCTTG-3' 
ABCG8 5'-CCGTCGTCAGATTTCCAATGA-3' 5'-GGCTTCCGACCCATGAATG-3' 
ACO 5’-ACGTCTTGGATGGTAGTCCG-3’ 5’-TAACGCTGGCTTCGAGTGAG-3’ 
BSEP 5’-GTCTGACTCAGTGATTCTTCGC-3’ 5’-GAGCAATGCGCACACACTTC-3’ 
ChREBP 5’-CTGGGGACCTAAACAGGAGC-3’ 5’-GAAGCCACCCTATAGCTCCC-3’ 
Cyp3A11 5’-TAAGCAGAAGCACCGAGTGG-3’ 5’-ATTGACTGGGCTGTGATCTCC-3’ 
CD36 5’-GCACCACTGTGTACAGACAG-3’ 5’-GTGCAGCTGCTACAGCCAG-3’ 
FAE 5’-CATGCCGTCATGTACTCTTAC-3’ 5’-ATCTGAGTGATCTGGGACAAG-3’ 
DIO1 5’-CAGCTATGGCTGTGGCTG-3’ 5’-CCTACAGCCACCTCCAAG-3’ 
NPC1L1 5’-ATCCTCATCCTGGGCTTTGC-3’ 5’-GCAAGGTGATCAGGAGGTTGA-3’ 
 
 
 
Supplemental Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 1 : Influence of bexarotene and T0901317 treatment on the expression 
of target genes of different RXR partners in the liver 
Hepatic mRNA levels of ACO, BSEP, ChREBP, DIO1 (A), Cyp3A11, CD36 and FAE (B) were 
measured in LXRα/β-deficient mice () and wild type mice () gavaged with the RXR agonist 
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(bexarotene, 30 and 100 mpk), the LXR agonist (T0901317, 30 mpk) or vehicle alone for 14 days 
(N=7/group). Data normalized to 28S RNA are expressed as a percentage of the wild type mice group 
treated with vehicle alone, to which an arbitrary value of 100 was attributed. *p<0.05, **p<0.01, 
***p<0.001 versus wild type mice treated with vehicle, §p<0.05, §§p<0.01, §§§p<0.001 versus LXRα/β-
deficient mice treated with vehicle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 2 : Influence of bexarotene and T0901317 treatment on the expression 
of ABCG5, ABCG8 and NPC1L1 in the jejunum 
mRNA levels of ABCG5,  ABCG8 and NPC1L1 were measured in the jejunum of LXRα/β-deficient 
mice () and wild type mice () gavaged with the RXR agonist (bexarotene, 30 and 100 mpk), the LXR 
agonist (T0901317, 30 mpk) or vehicle alone for 14 days (N=7/group). Data normalized to 28S RNA 
are expressed as a percentage of the wild type mice group treated with vehicle alone, to which an 
arbitrary value of 100 was attributed. *p<0.05, **p<0.01, ***p<0.001 versus wild type mice treated with 
vehicle, §§p<0.01, §§§p<0.001 versus LXRα/β-deficient mice treated with vehicle. 
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